Table 2.
Clinicopathological variables of patients according to PD-1, PD-L1, PD-L2, IDO-1, IDO-2, INFγ gene expression levels.
| Variables | PD-1, N. (%) | PD-L1, N. (%) | PD-L2, N. (%) | IDO-1, N. (%) | IDO-2, N. (%) | INFγ, N. (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Low | High | Low | High | Low | High | Low | High | Low | High | Low | High | |
| N | 151 (79.1) | 40 (20.9) | 77 (40.3) | 114 (59.7) | 103 (53.4) | 88 (46.1) | 110 (57.6) | 81 (42.4) | 130 (68.1) | 61 (31.9) | 157 (82.2) | 34 (17.8) |
| Age (years) | ||||||||||||
| <60 | 24 (12.6) | 10 (5.2) | 11 (5.8) | 23 (12.0) | 12 (6.3) | 22 (11.5) | 16 (8.4) | 18 (9.4) | 22 (11.5) | 12 (6.3) | 25 (13.1) | 9 (4.7) |
| ≥60 | 127 (66.5) | 30 (15.7) | 66 (34.6) | 91 (47.6) | 91 (47.6) | 66 (34.6) | 94 (49.2) | 63 (33.0) | 108 (56.5) | 49 (25.7) | 132 (69.1) | 25 (13.1) |
| p = 0.181 | p = 0.297 | p = 0.016 | p = 0.170 | p = 0.643 | p = 0.145 | |||||||
| Sex | ||||||||||||
| Female | 45 (23.6) | 9 (4.7) | 18 (9.4) | 36 (18.9) | 32 (16.8) | 22 (11.5) | 31 (16.2) | 23 (12.0) | 42 (22.0) | 12 (6.3) | 46 (24.1) | 8 (4.2) |
| Male | 106 (55.5) | 31 (16.2) | 59 (30.9) | 78 (40.8) | 71 (37.2) | 66 (34.5) | 79 (41.4) | 58 (30.4) | 88 (46.1) | 49 (25.6) | 111 (58.1) | 26 (13.6) |
| p = 0.362 | p = 0.217 | p = 0.353 | p = 0.974 | p = 0.071 | p = 0.675 | |||||||
| Smoking | ||||||||||||
| Never | 15 (7.9) | 1 (0.5) | 6 (3.1) | 10 (5.2) | 8 (4.2) | 8 (4.2) | 7 (3.7) | 9 (4.7) | 14 (7.3) | 2 (1.1) | 14 (7.3) | 2 (1.1) |
| Current | 59 (30.9) | 17 (8.9) | 30 (15.7) | 46 (24.1) | 40 (20.9) | 36 (18.9) | 44 (23.0) | 31 (16.8) | 48 (25.1) | 28 (14.7) | 62 (32.5) | 14 (7.3) |
| Former | 77 (40.3) | 22 (11.5) | 41 (21.5) | 58 (30.4) | 55 (28.8) | 44 (23.0) | 59 (30.9) | 40 (20.9) | 68 (35.6) | 31 (16.2) | 81 (42.4) | 18 (9.4) |
| p = 0.388 | p = 0.975 | p = 0.882 | p = 0.502 | p = 0.162 | p = 0.920 | |||||||
| Histology | ||||||||||||
| Invasive Adenocarcinomas | 104 (54.4) | 16 (8.4) | 54 (28.3) | 66 (34.6) | 73 (38.2) | 47 (24.6) | 73 (38.2) | 47 (24.6) | 95 (49.7) | 25 (13.1) | 100 (52.4) | 20 (10.5) |
| Squamous | 45 (23.6) | 24 (12.6) | 23 (12.0) | 46 (24.1) | 29 (15.2) | 40 (21.0) | 36 (18.9) | 33 (17.3) | 33 (17.3) | 36 (18.9) | 55 (28.8) | 14 (7.3) |
| Adenosquamous | 2 (1.0) | 0 (0.0) | 0 (0.0) | 2 (1.0) | 1 (0.5) | 1 (0.5) | 1 (0.5) | 1 (0.5) | 2 (1.0) | 0 (0.0) | 2 (1.0) | 0 (0.0) |
| p = 0.001 | p = 0.146 | p = 0.021 | p = 0.498 | p < 0.001 | p = 0.702 | |||||||
| Grading | ||||||||||||
| 1 | 8 (4.2) | 3 (1.6) | 2 (1.0) | 9 (4.7) | 5 (2.6) | 6 (3.2) | 3 (1.6) | 8 (4.2) | 7 (3.7) | 4 (2.1) | 7 (3.7) | 4 (2.1) |
| 2 | 81 (42.4) | 18 (9.4) | 43 (22.5) | 56 (29.3) | 55 (28.8) | 44 (23.0) | 61 (31.9) | 38 (19.9) | 74 (38.7) | 25 (13.1) | 82 (43) | 17 (8.9) |
| 3 | 62 (32.5) | 19 (9.9) | 32 (16.8) | 49 (25.7) | 43 (22.5) | 38 (19.9) | 46 (24.1) | 35 (18.3) | 49 (25.7) | 32 (16.7) | 68 (35.6) | 13 (6.8) |
| p = 0.540 | p = 0.299 | p = 0.818 | p = 0.094 | p = 0.107 | p = 0.261 | |||||||
| p-Stage | ||||||||||||
| I | 89 (46.6) | 12 (6.3) | 49 (25.7) | 52 (27.2) | 59 (30.9) | 42 (22.0) | 65 (34.0) | 36 (18.9) | 80 (41.9) | 21 (11.0) | 87 (45,5) | 14 (7.3) |
| II | 39 (20.4) | 17 (8.9) | 18 (9.4) | 38 (19.9) | 28 (14.7) | 28 (14.7) | 31 (16.2) | 25 (13.1) | 31 (16.2) | 25 (13.1) | 45 (23.6) | 11 (5.8) |
| III | 23 (12.0) | 11 (5.8) | 10 (5.2) | 24 (12.6) | 16 (8.3) | 18 (9.4) | 14 (7.3) | 20 (10.5) | 19 (9.9) | 15 (7.9) | 25 (13.1) | 9 (4.7) |
| p = 0.005 | p = 0.048 | p = 0.404 | p = 0.059 | p = 0.002 | p = 0.208 | |||||||
Abbreviations: PD-1, programmed cell death 1; PD-L1, programmed cell death 1 ligand 1; PD-L2, programmed cell death 1 ligand 2; IDO-1, indoleamine 2,3-dioxygenase 1; IDO-2, indoleamine 2,3-dioxygenase 2; INFγ, Interferon-γ; significant p value ≤ 0.05 in bold.